Behavioural Pharmacology
October 6, 2011
Irina Majumder, Jason M. White, Rodney James Irvine
16 citations
Increased synaptic serotonin (5-hydroxytryptamine) levels may underlie antidepressant-like effects of 3,4-methylenedioxymethamphetamine (MDMA) that may be more prominent in subjects with mood disturbance. The Flinders Sensitive Line (FSL) strain is an important animal model of depression. These rats are more immobile in the forced swimming test (FST), and their immobility is reversed by known...
Behavioural Pharmacology
September 1, 2011
Mary Melissa Peet, Lisa E Baker
21 citations
Salvinorin A, the main active component of Salvia divinorum, is a potent and selective κ opioid receptor agonist. Synthetic derivatives of this substance may be useful in the development of medicinal treatments for pain, mood disorders, and drug dependence. Such developments require extensive preclinical screening of these compounds. The drug discrimination assay is a valuable method for...
Behavioural Pharmacology
September 2011
Torbjörn U C Järbe, Hongfen Deng, Subramanian K Vadivel et al.
We examined four different cannabinergic aminoalkylindole ligands, including one drug (AM678=JWH018) found in herbal 'Spice' concoctions, for their ability to substitute for Δ(9)-tetrahydrocannabinol (THC), and the ability of the cannabinoid receptor 1-selective antagonist/inverse agonist rimonabant to block the substitution, 30 and 90 min after intraperitoneal injection. Rats trained to...
Behavioural Pharmacology
September 2011
Jenny L Wiley, D Matthew Walentiny, Robert E Vann et al.
Δ(9)-Tetrahydrocannabinol (THC) discrimination in rodents is a behavioral assay that has been used to probe differences among classes of cannabinoids in rats. The purpose of this study was to determine whether traditional and anandamide-like cannabinoids were distinguishable in cannabinoid discrimination procedures in mice. Male mice were trained to discriminate 30 mg/kg THC or 70 mg/kg...
Behavioural Pharmacology
September 2011
Alexa A Wakley, Rebecca M Craft
This study examined cannabinoid-opioid interactions within the same subjects on measures of discrimination, antinociception, horizontal locomotion, and catalepsy. Male Sprague-Dawley rats were trained to discriminate Δ(9)-tetrahydrocannabinol (THC, 3 mg/kg) from vehicle. THC alone (0.32-10 mg/kg) dose-dependently increased THC-appropriate lever responding and decreased response rate. THC alone...
Behavioural Pharmacology
June 29, 2011
María José Varela, José Brea, Marı́a Isabel Loza et al.
18 citations
The behavioral and neurochemical adaptations related to chronic 3,4-methylenedioxymethamphetamine (MDMA) treatment are largely unknown. In this study, we assessed whether repeated administration of MDMA would induce (a) context-dependent locomotor sensitization in mice and (b) changes in serotonin 5-HT(2A) and dopamine D₂ receptor functionality as measured by [³⁵S]GTPγS binding. Mice were...
Behavioural Pharmacology
June 2011
Katarzyna Fijal, Piotr Popik
Transitive inference, that is, the ability to infer relationships among stimuli that are only indirectly associated, is impaired in schizophrenic patients and in rats with lesions of the prefrontal cortex. Symptoms of schizophrenia can be pharmacologically modeled by administration of the N-methyl-D-aspartate receptor antagonist, phencyclidine (PCP). Here, a subchronic administration of PCP...
Behavioural Pharmacology
April 8, 2011
Adam Stewart, Russell Riehl, Keith Wong et al.
66 citations
3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') is a potent psychedelic drug inducing euphoria and hypersociability in humans, as well as hyperactivity and anxiety in rodents. Adult zebrafish (Danio rerio) have become a widely used species in neurobehavioral research. Here, we explore the effects of a wide range (0.25-120 mg/l) of acute MDMA doses on zebrafish behavior in the novel tank...
Behavioural Pharmacology
December 2009
Katharine A Brennan, Caleb Carati, Rod A Lea et al.
It has been suggested that activation of dopamine D1-like and D2-like receptors contribute equally to the maintenance of drug self-administration. This study compared the contribution of these receptor subtypes to 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MA) self-administration. Effects of pretreatment with the D2-like receptor antagonist, eticlopride (0.0, 0.0125, 0.025 or...
Behavioural Pharmacology
July 2008
Matthew L Banks, Robert W Gould, Paul W Czoty et al.
Concurrent schedules of reinforcement are increasingly being used to investigate the reinforcing strength of abused drugs. A purported advantage of concurrent schedules is that the primary dependent measure, percentage of responses emitted on the drug-associated manipulandum, is independent of the rate-altering effects of drugs. Data supporting this hypothesis are, however, rarely presented,...
Behavioural Pharmacology
July 2008
Christopher S Breivogel, Jonathan M Lambert, Steven Gerfin et al.
Little is known about the roles of beta-arrestins in the regulation of brain CB1 cannabinoid receptors. This study investigated the role of beta-arrestin2 in cannabinoid behavioral effects using beta-arrestin2 -/- mice and their wild-type counterparts. A variety of cannabinoid ligands from different chemical classes that exhibit a variety of efficacies for activation of CB1 receptors were...
Behavioural Pharmacology
March 2008
Matthew R. Skelton, Michael T. Williams, Charles V. Vorhees
+/-3,4-Methylenedioxymethamphetamine (MDMA) is a chemical derivative of amphetamine that has become a popular drug of abuse and has been shown to deplete serotonin in the brains of users and animals exposed to it. To date, most studies have investigated the effects of MDMA on adult animals. With a majority of users of MDMA being young adults, the chances of the users becoming pregnant and...
Behavioural Pharmacology
March 2008
Matthew L Banks, Paul W Czoty, Jon E. Sprague et al.
In monkeys, elevating ambient temperature has been shown to increase sensitivity to 3,4-methylenedioxymethamphetamine (MDMA) reinforcement. Earlier rodent studies have shown that elevations in thyroid levels (hyperthyroidism) parallel changes in elevating the ambient temperature on MDMA-induced thermogenesis, but the interaction has not been examined in monkeys. This study was designed to...
Behavioural Pharmacology
September 2007
Young May Cha, Katherine H Jones, Cynthia M Kuhn et al.
Like other recreational drugs, cannabinoids may produce different effects in men and women. In this study we measured the effects of delta9-tetrahydrocannabinol (THC) on spatial learning in two groups that are underrepresented in drug research--females and adolescents. In the first experiment, adolescent (postnatal day 30) and adult (postnatal day 70) rats of both sexes were treated...
Behavioural Pharmacology
March 2006
Lori M Lieving, Scott D Lane, Don R Cherek et al.
Marijuana has been reported to alter the discrimination of time. The present study used a psychophysical approach to examine the effects of marijuana on temporal discrimination in humans. Research participants were required to push one of two buttons depending on the duration of a conditional stimulus (a blue square on a computer monitor). Correct choices ('C' button after a 2-s stimulus; 'A'...
Behavioural Pharmacology
December 1, 2005
William E Fantegrossi, Kelly M Kugle, Leander J. Valdés et al.
80 citations
Salvinorin A is a pharmacologically active diterpene that occurs naturally in the Mexican mint Ska Maria Pastora (Salvia divinorum) and represents the first naturally occurring kappa-opioid receptor agonist. The chemical structure of salvinorin A is novel among the opioids, and thus defines a new structural class of kappa-opioid-receptor selective drugs. Few studies have examined the effects of...
Behavioural Pharmacology
September 1, 2005
Aaron B Ilan, Alan Gevins, Michael J. Coleman et al.
165 citations
This study investigated the contribution of different cannabinoids to the subjective, behavioral and neurophysiological effects of smoked marijuana. Healthy marijuana users (12 men, 11 women) participated in four sessions. They were randomly assigned to a low or a high delta9-tetrahydrocannabinol group (THC; 1.8% versus 3.6%). In the four sessions under blinded conditions subjects smoked...
Behavioural Pharmacology
September 2005
Lance R Mcmahon, M R Amin, Charles P France
The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC). This study examined the effects of SR 141716A on the rate-decreasing, hypothermic and discriminative stimulus effects of delta9-THC in rhesus monkeys. In monkeys (n=4) responding...
Behavioural Pharmacology
September 2005
P J McLaughlin, C M Brown, K M Winston et al.
Cannabinoid agonists have been shown to produce dose-related impairments in several measures of cognitive performance. However, it is unclear if low doses of cannabinoid CB1 agonists, or CB1 antagonists, can facilitate aspects of stimulus detection. The present study employed an operant procedure involving visual stimulus detection in rats. The task was found to be sensitive to the muscarinic...
Behavioural Pharmacology
September 2005
J M Witkin, Eleni T. Tzavara, George G. Nomikos
Mood and anxiety disorders, the most prevalent of the psychiatric disorders, cause immeasurable suffering worldwide. Despite impressive advances in pharmacological therapies, improvements in efficacy and side-effect profiles are needed. The present literature review examines the role that the endocannabinoid system may play in these disorders and the potential value of targeting this system in...
Behavioural Pharmacology
March 1, 2005
V. Buben Kov, Martin Votava, J. Hora Ek et al.
38 citations
Sensorimotor gating is the ability of a weak sensory event to inhibit the motor response to an intense stimulus. Drugs that act as serotonin releasers, such as MDMA (3,4-methylenedioxymethamphetamine), impair sensorimotor gating, which is measured as a prepulse inhibition (PPI) of the acoustic startle response. The first objective of the present study was to compare the effect of different...
Behavioural Pharmacology
February 1, 2005
J Podhorna, M Didriksen
In order to establish an animal model of cognitive impairments relevant to schizophrenia, we set out to obtain an optimal treatment protocol with phencyclidine (PCP) that would lead to robust cognitive impairment with minimal PCP-related adverse effects. Effects of various doses (0.63-5 mg/kg), pre-treatment period (0, 3, 7 and 10 days before the beginning of acquisition) and treatment...
Behavioural Pharmacology
July 2004
Scott D Lane, Don R Cherek, C J Pietras et al.
Acute marijuana administration may alter response-reinforcer relationships via a change in reinforcer efficacy, but may also impair coordination and motor function. One approach to evaluating drug effects on both motor function and reinforcer efficacy involves fitting the matching law equation to data obtained under multiple variable interval (VI) schedules. The present report describes an...
Behavioural Pharmacology
March 1, 2004
William E Fantegrossi, James H Woods, Gail Winger
99 citations
Relatively few studies have assessed the reinforcing effects of hallucinogenic compounds, and no such studies have attempted to engender contingent responding for these compounds in animals with behavioral histories that include experience with serotonergically mediated reinforcing effects. The objectives of the present study were to investigate the capacity of several hallucinogenic compounds...
Behavioural Pharmacology
July 2002
D Van Oekelen, Anton A. H. P. Megens, Theo Meert et al.
We distinguished the functions of the different 5-hydroxytryptamine-2 (5-HT(2)) receptor (5-HT(2)R) subtypes in the tryptamine-induced 5-HT syndrome in rats using (1) the 5-HT(2A)R antagonist R93274 (N-[(3-p-fluorophenyl-1-propyl)-4-methyl-4-piperidinyl]-4-amino-5-iodo-2-methoxybenzamide), the 5-HT(2A/C)R antagonist R99647...